Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

Compass Point is pleased to announce the expansion of its Real Estate Research Team with the addition of Mr. Robert Simone. Compass Point remains committed to attracting exceptional professionals who ...

(MENAFN- EIN Presswire) EINPresswire/ -- Compass Point, a leading full-service middle market investment bank, is pleased to announce the expansion of its Real Estate Research Team with the addition of ...

Investing.com - Compass Point initiated coverage on BitGo Holdings (NYSE:BTGO) with a Buy rating and set a price target of $17.00, according to a research note published Monday. This target represents ...

Investing.com - Compass Point upgraded Upstart Holdings Inc (NASDAQ:UPST) to Neutral from Sell on Tuesday and raised its price target to $30 from $20, closely aligning with the stock’s current trading ...

Ed Engel, Compass Point senior research analyst, joins 'The Exchange' to discuss a potential bottom in crypto prices, what another retest of the lows could mean and much more. Got a confidential news ...

Upstart Holdings Inc. (NASDAQ:UPST) is one of the best growth stocks to buy for the next 20 years. On February 17, following the company’s Q4 2025 earnings report, Compass Point analyst Giuliano ...

Compass Point is adopting a bullish stance on Nebius Group . The firm initiated the artificial intelligence infrastructure stock with a buy rating and price target of $150, implying upside of 54%.